Mohit K Turagam1, Moustapha Atoui2, Donita Atkins3, Luigi Di Biase4, Kalyanam Shivkumar5, T Jared Bunch6, Sanghamitra Mohanty7, Carola Gianni7, Andrea Natale7, Dhanunjaya Lakkireddy8,9. 1. Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. St. Cloud Hospital, St. Cloud, MN, USA. 3. Kansas City Heart Rhythm Institute & Research Foundation, Overland Park Regional Medical Center, HCA MidWest, Kansas City, KS, 66221, USA. 4. Montefiore Medical Center, Bronx, NY, USA. 5. UCLA Medical Center, Los Angeles, CA, USA. 6. Intermountain Medical Center, Murray, UT, USA. 7. Texas Cardiac Arrhythmia Center, Austin, TX, USA. 8. Kansas City Heart Rhythm Institute & Research Foundation, Overland Park Regional Medical Center, HCA MidWest, Kansas City, KS, 66221, USA. dhanunjaya.lakkireddy@hcahealthcare.com. 9. Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, KS, 66221, USA. dhanunjaya.lakkireddy@hcahealthcare.com.
Abstract
BACKGROUND: Persistent left superior vena cava (PLSVC) is one of the most frequently reported congenital anomalies and may be an important source of trigger of atrial fibrillation (AF). METHODS: This was a multicenter retrospective experience including 28 patients with PLSVC who were referred for catheter ablation for drug-refractory symptomatic AF. Pulmonary vein and PLSVC isolation were performed (3.5-mm open irrigated tip ablation catheter at maximum power of 20 W, maximum temperature 43 °C with flow rate of 17 ml/min). Clinical outcomes such as complications and long-term freedom from AF were measured. RESULTS: The mean age of the population was 61 ± 8 years, 21% were females, and AF duration was 60 ± 33 months. Sixty-one percent paroxysmal AF (17/28), 25% (7/28) persistent AF, and 14% (4/28) had long-standing persistent AF. There were no major complications that required any intervention. PLSVC isolation was achieved in 96% (27/28). Freedom from AF at 1 year without antiarrhythmic drugs was seen in 75% (21/28) of patients. CONCLUSIONS: In PLSVC patients with AF, segmental isolation of PLSVC appears to be feasible and safe and can translate into favorable clinical outcomes.
BACKGROUND: Persistent left superior vena cava (PLSVC) is one of the most frequently reported congenital anomalies and may be an important source of trigger of atrial fibrillation (AF). METHODS: This was a multicenter retrospective experience including 28 patients with PLSVC who were referred for catheter ablation for drug-refractory symptomatic AF. Pulmonary vein and PLSVC isolation were performed (3.5-mm open irrigated tip ablation catheter at maximum power of 20 W, maximum temperature 43 °C with flow rate of 17 ml/min). Clinical outcomes such as complications and long-term freedom from AF were measured. RESULTS: The mean age of the population was 61 ± 8 years, 21% were females, and AF duration was 60 ± 33 months. Sixty-one percent paroxysmal AF (17/28), 25% (7/28) persistent AF, and 14% (4/28) had long-standing persistent AF. There were no major complications that required any intervention. PLSVC isolation was achieved in 96% (27/28). Freedom from AF at 1 year without antiarrhythmic drugs was seen in 75% (21/28) of patients. CONCLUSIONS: In PLSVC patients with AF, segmental isolation of PLSVC appears to be feasible and safe and can translate into favorable clinical outcomes.
Entities:
Keywords:
Atrial fibrillation; Congenital anomaly; Persistent left superior vena cava syndrome; Radiofrequency ablation